MRK Merck KGAA

   By Cecilia Butini 
 

Merck KGaA on Thursday posted higher earnings and sales for the second quarter and raised its outlook for the full year.

The German pharmaceuticals-and-chemicals company posted after-tax profit of 747 million euros ($884.3 million) for the quarter, compared with EUR289 million in the same period a year earlier, on sales which grew to EUR4.87 billion from EUR4.12 billion in the same quarter of 2020.

Sales were driven by the company's healthcare pipeline, its process solutions and semiconductor solutions segments, it said.

Earnings before interest, taxes, depreciation and amortization before one-time items, or Ebitda pre, stood at EUR1.58 billion, compared with EUR1.07 billion in the same quarter of 2020, Merck said.

For the full year, the company raised its forecasts and said it now expects organic growth of 12% to 14%, compared with a previous range of 10% to 12%. Net sales are seen coming in between EUR18.8 billion and EUR19.7 billion, compared with a previous forecast that saw them between EUR18.5 billion and EUR19.5 billion, Merck said.

Ebitda pre is now expected between EUR5.6 billion and EUR6 billion, up from a previous forecast of between EUR5.4 billion and EUR5.8 billion, the company said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

August 05, 2021 01:37 ET (05:37 GMT)

Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Merck KGAA (TG:MRK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024